IMCD Acquires Indian Pharma Supplier Trichem
IMCD, a global partner for the distribution and formulation of speciality chemicals and ingredients, has acquired 100% of the shares in Trichem, an Indian pharmaceutical supplier.
Founded in 1998 and headquartered in Mumbai, India, Trichem supplies high-quality active pharmaceutical ingredients, pharmaceutical intermediates, and formulation solutions. The company also provides regulatory assistance for customers serving the highly regulated pharmaceutical markets in India.
Trichem operates across India and the Middle East, generating annual revenue of approximately INR 1.7 billion (ca. €18 million) for the financial year ended March 31, 2025. About 33% of this revenue comes from commission income.
"With India being a major supplier of the world’s generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients, and reinforces our position in the region’s life-sciences industry," said Narendra Varde, Managing Director of IMCD India. "Additionally, we are excited to welcome Trichem’s talented team, whose deep market expertise and strong industry relationships will be invaluable to IMCD."
Chetan Jain, Founder and Promoter of Trichem Group, added: "IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships. I am extremely proud of Trichem’s achievements over the past 27 years. Going forward with IMCD’s global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders.”
